Biblio Discovery — Demo Discovery Service

5 hasil untuk "Devika Patel"

Menampilkan 1–5 · 0,78 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda

    Adithya Cattamanchi; Rebecca Crowder; Alex Kityamuwesi dkk.

    PLOS Medicine, Vol. 18 No. 5 · 2021 · Inggris · PLOS Scopus

    Background: Adherence to and completion of tuberculosis (TB) treatment remain problematic in many high-burden countries. 99DOTS is a low-cost digital adherence technology that could increase TB treatment completion. Methods and findings: We conducted a pragmatic stepped-wedge cluster-randomized…

  2. Artikel Jurnal Teks lengkap

    Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-susceptible TB in Uganda

    Noah Kiwanuka; Alex Kityamuwesi; Rebecca Crowder dkk.

    PLOS Digital Health, Vol. 2 No. 6 · 2023 · Inggris · PLOS Scopus

    99DOTS is a low-cost digital adherence technology that allows people with tuberculosis (TB) to self-report treatment adherence. There are limited data on its implementation, feasibility, and acceptability from sub-Saharan Africa. We conducted a longitudinal analysis and cross-sectional surveys…

  3. Artikel Jurnal Teks lengkap

    Completion of isoniazid–rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness–implementation randomized trial

    Fred C. Semitala; Jillian L. Kadota; Allan Musinguzi dkk.

    PLOS Medicine, Vol. 18 No. 12 · 2021 · Inggris · PLOS Scopus

    Background: Scaling up shorter regimens for tuberculosis (TB) prevention such as once weekly isoniazid–rifapentine (3HP) taken for 3 months is a key priority for achieving targets set forth in the World Health Organization’s (WHO) END TB Strategy. However, there are few data on 3HP patient…

  4. Artikel Jurnal Teks lengkap

    Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial

    Fred C. Semitala; Jillian L. Kadota; Allan Musinguzi dkk.

    PLOS Medicine, Vol. 21 No. 2 · 2024 · Inggris · PLOS Scopus

    Background: Expanding access to shorter regimens for tuberculosis (TB) prevention, such as once-weekly isoniazid and rifapentine taken for 3 months (3HP), is critical for reducing global TB burden among people living with HIV (PLHIV). Our coprimary hypotheses were that high levels of acceptance and…

  5. Artikel Jurnal Teks lengkap

    Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial

    Allan Musinguzi; Joan R. Kasidi; Jillian L. Kadota dkk.

    PLOS Global Public Health, Vol. 4 No. 10 · 2024 · Inggris · PLOS Scopus

    Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify factors influencing successful 3HP delivery. We conducted a qualitative assessment of 3HP…